Bromide

Bromide

SCHEMBL813558

CCc1cc(CC)c(NCCN(C)CCNc2c(C)cc(C)cc2C)c(CC)c1.[Br-].[Br-].[Co+2]

nearest known ligand 0.35

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
RAPGEF4 Q8WZA2 2/20 0.35
CYP3A4 P08684 1/20 0.33
HPGD P15428 1/20 0.32
FFAR4 Q5NUL3 1/20 0.31
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL812434 0.97 RAPGEF4 (0.35) RAPGEF4CYP3A4HPGDFFAR4TSHR
Bromide SCHEMBL813359 0.90 MEN1 (0.30)
Bromide SCHEMBL813702 0.88 ALDH1A1 (0.36) RAPGEF4CYP3A4HPGD
Hydrochloric Acid SCHEMBL813375 0.87 MEN1 (0.30)
Bromide SCHEMBL814475 0.86 GAA (0.39) RAPGEF4CYP3A4HPGD
Hydrochloric Acid SCHEMBL814504 0.85 MEN1 (0.31)
Bromide SCHEMBL813103 0.85 RAPGEF4 (0.41) RAPGEF4CYP3A4HPGD
Hydrochloric Acid SCHEMBL813027 0.85 ALDH1A1 (0.36) RAPGEF4CYP3A4HPGD
Bromide SCHEMBL813530 0.84 BCHE (0.32)
Bromide SCHEMBL813814 0.84 RAPGEF4 (0.38) RAPGEF4HPGDFFAR4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8058372-B2 Catalyst composition II EXXONMOBIL CHEMICAL PATENTS INC. (US) 2011-11-15 US disclosed
US-20080319147-A1 Catalyst Composition II EXXONMOBIL CHEMICAL PATENTS INC. 2008-12-25 US disclosed
US-7371803-B2 Catalyst composition II EXXONMOBIL CHEMICAL PATENTS INC. (US) 2008-05-13 US disclosed
US-20070066776-A1 Catalyst composition II SOLAN GREGORY A 2007-03-22 US disclosed
US-7189791-B2 Catalyst composition II EXXONMOBIL CHEMICAL PATENTS INC. (US) 2007-03-13 US disclosed
EP-1641842-A2 POLYMERIZATION AND OLIGOMERIZATION CATALYST WITH TRIDENTATE OR TETRADENTATE LIGAND Exxonmobil Chemical Patents Inc. (US) 2006-04-05 EP disclosed
US-20040266961-A1 Catalyst composition II EXXONMOBIL CHEMICAL PATENTS INC. 2004-12-30 US disclosed
WO-2004106390-A2 POLYMERIZATION AND OLIGOMERIZATION CATALYST WITH TRIDENTATE OR TETRADENTATE LIGAND EXXONMOBIL CHEMICAL PATENTS INC. (US) 2004-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266961-A1 Catalyst composition II MLX, CBX2, BMX RAPGEF4 4437/4885CYP3A4 2959/4885HPGD 3572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.